Marilla Lucero
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Marilla Lucero has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Gail Marilyn Williams
School of Public Health, University of Queensland, Brisbane, QLD 4006, Australia
3 shared publications Hanna Nohynek
2 shared publicationsHelena Käyhty
National Public Health Institute (KTL), Helsinki, Finland
2 shared publications- Anu Soininen
National Institute for Health and Welfare, Department of Vaccination and Immune Protection, Mannerheimintie 166, 00300 Helsinki, Finland
1 shared publication - Arnaldo F. Ocampo
Bohol Regional Hospital, Tagbilaran City, Bohol, Philippines
1 shared publication Christel Biltoft
National Public Health Institute (KTL), Helsinki, Finland
1 shared publication
Latest Publications
- Open Access
- 18 January 2013
- Published by Springer Nature
Evaluation of alternative vaccination schedules for Pneumococcal Conjugate Vaccine (PCV) (Philippines)
- 18 January 2013
- Published by Springer Nature
Open AccessEvaluation of alternative vaccination schedules for Pneumococcal Conjugate Vaccine (PCV) (Philippines)
- 1 March 2005
- Published by Elsevier in The Lancet
- Vol. 365 (9465) , 1113-4
Vaccine trial as "probe" to define the burden of pneumococcal pneumonia disease.
- 1 March 2005
- Published by Elsevier in The Lancet
- Vol. 365 (9465) , 1113-4
Vaccine trial as "probe" to define the burden of pneumococcal pneumonia disease.
- 18 October 2004
- Published by Wiley
- No. 4,p. CD004977
Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and pneumonia with consolidation on x-ray in children under two years of age
Pneumonia, most commonly caused by Streptococcus pneumoniae (Pnc), is a major cause of morbidity and mortality among young children especially in developing countries. Recently, the prevalence of antibiotic‐resistant Pnc has increased worldwide such that the effectiveness of preventive strategies, like the new pneumococcal conjugate vaccines (PCV) on rates of invasive pneumococcal disease (IPD) and pneumonia, needs to be evaluated. To determine the efficacy of PCV in reducing the incidence of IPD due to vaccine serotypes (VT) and x‐ray confirmed pneumonia with consolidation of unspecified etiology in children who received PCV before 12 months of age. We searched the following databases: the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library, 2004, issue 1) which contains the Acute Respiratory Infections Groups specialized register, MEDLINE (1990 to March 2004) and EMBASE (1990 to December 2003). Reference list of articles, and books of abstracts of relevant symposia, were hand searched. Researchers in the field were also contacted. Randomised controlled trials (RCTs) comparing PCV with placebo, or another vaccine, among children below two years with IPD and clinical/radiographic pneumonia as outcomes. Two review authors independently identified eligible studies, assessed trial quality, and extracted data. Differences were resolved by discussion. The inverse variance method was used to pool effect sizes. We identified four trials assessing the efficacy of PCV in reducing the incidence of IPD, two on x‐ray confirmed pneumonia as outcome, and one on clinical pneumonia, with or without x‐ray confirmation. Results from pooling HIV‐1 negative children from the South African study with the other studies were as follows: the pooled vaccine efficacy (VE) for vaccine‐type IPD was 88% (95% confidence interval (CI) 73% to 94%; fixed‐effect and random‐effects models), the effect measure was statistically significant (P 2 0%); the pooled VE for all‐serotype IPD was 66% (95% CI 46% to 79%; fixed‐effect model), the effect measure was statistically significant (P 2 51%); the pooled VE for x‐ray confirmed pneumonia was 22% (95% CI 11% to 31%; both fixed‐effect and random‐effects models) and there was no statistical heterogeneity (P = 0.80, I2 0%). Analyses that included all the children in the South African study (HIV‐1 negative and HIV‐1 positive children) and pooled with data from the other studies gave very similar results. PCV is effective in reducing the incidence of IPD from all serotypes but exerts a greater effect in reducing VT IPD. Although PCV is also effective in reducing the incidence of x‐ray confirmed pneumonia, there are still uncertainties about the definition of this outcome. Additional randomised controlled trials are currently in progress.
- 18 October 2004
- Published by Wiley
- No. 4,p. CD004977
Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and pneumonia with consolidation on x-ray in children under two years of age
Pneumonia, most commonly caused by Streptococcus pneumoniae (Pnc), is a major cause of morbidity and mortality among young children especially in developing countries. Recently, the prevalence of antibiotic‐resistant Pnc has increased worldwide such that the effectiveness of preventive strategies, like the new pneumococcal conjugate vaccines (PCV) on rates of invasive pneumococcal disease (IPD) and pneumonia, needs to be evaluated. To determine the efficacy of PCV in reducing the incidence of IPD due to vaccine serotypes (VT) and x‐ray confirmed pneumonia with consolidation of unspecified etiology in children who received PCV before 12 months of age. We searched the following databases: the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library, 2004, issue 1) which contains the Acute Respiratory Infections Groups specialized register, MEDLINE (1990 to March 2004) and EMBASE (1990 to December 2003). Reference list of articles, and books of abstracts of relevant symposia, were hand searched. Researchers in the field were also contacted. Randomised controlled trials (RCTs) comparing PCV with placebo, or another vaccine, among children below two years with IPD and clinical/radiographic pneumonia as outcomes. Two review authors independently identified eligible studies, assessed trial quality, and extracted data. Differences were resolved by discussion. The inverse variance method was used to pool effect sizes. We identified four trials assessing the efficacy of PCV in reducing the incidence of IPD, two on x‐ray confirmed pneumonia as outcome, and one on clinical pneumonia, with or without x‐ray confirmation. Results from pooling HIV‐1 negative children from the South African study with the other studies were as follows: the pooled vaccine efficacy (VE) for vaccine‐type IPD was 88% (95% confidence interval (CI) 73% to 94%; fixed‐effect and random‐effects models), the effect measure was statistically significant (P 2 0%); the pooled VE for all‐serotype IPD was 66% (95% CI 46% to 79%; fixed‐effect model), the effect measure was statistically significant (P 2 51%); the pooled VE for x‐ray confirmed pneumonia was 22% (95% CI 11% to 31%; both fixed‐effect and random‐effects models) and there was no statistical heterogeneity (P = 0.80, I2 0%). Analyses that included all the children in the South African study (HIV‐1 negative and HIV‐1 positive children) and pooled with data from the other studies gave very similar results. PCV is effective in reducing the incidence of IPD from all serotypes but exerts a greater effect in reducing VT IPD. Although PCV is also effective in reducing the incidence of x‐ray confirmed pneumonia, there are still uncertainties about the definition of this outcome. Additional randomised controlled trials are currently in progress.
- Open Access
- 1 June 2004
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 189 (11) , 2077-2084
Similar Antibody Concentrations in Filipino Infants at Age 9 Months, after 1 or 3 Doses of an Adjuvanted, 11‐Valent Pneumococcal Diphtheria/Tetanus–Conjugated Vaccine: A Randomized Controlled Trial
In Filipino infants, 1 dose of an adjuvanted, 11-valent pneumococcal conjugate vaccine (serotypes 1, 4, 5, 7F, 9V, 19F, and 23F conjugated to tetanus
- 1 June 2004
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 189 (11) , 2077-2084
Open AccessSimilar Antibody Concentrations in Filipino Infants at Age 9 Months, after 1 or 3 Doses of an Adjuvanted, 11‐Valent Pneumococcal Diphtheria/Tetanus–Conjugated Vaccine: A Randomized Controlled Trial
In Filipino infants, 1 dose of an adjuvanted, 11-valent pneumococcal conjugate vaccine (serotypes 1, 4, 5, 7F, 9V, 19F, and 23F conjugated to tetanus